Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Representative image of bispecific antibody drug conjugate research as NEOK Bio highlights NEOK001 and NEOK002 at AACR 2026, drawing attention to the next wave of solid tumor ADC development.
Pharma & Biotech

Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?

NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.

Read More
Representative image of single-cell tumor analysis and clonal growth profiling, illustrating how SingleCell Biotechnology’s AACR 2026 assay could help link cancer cell behavior to molecular signatures in oncology drug discovery.
Pharma & Biotech

AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling

Read how SingleCell Biotechnology’s AACR 2026 assay could reshape tumor heterogeneity research and oncology drug development.

Read More
Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.
Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More
Representative image of preclinical oncology research linked to Soley Therapeutics’ STX-6398 program, highlighting the growing interest in CKAP2-targeted cancer drug discovery after AACR 2026.
Pharma & Biotech

Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?

Soley Therapeutics unveiled AACR 2026 data for STX-6398. Read why CKAP2 modulation could open a new path in oncology.

Read More
Pharma & Biotech

Akamis Bio AACR 2026 update: what early NG-350A data could mean for organ preservation

Akamis Bio’s NG-350A showed early promise in rectal cancer. Read what the Fortress data could change, and what still needs proving.

Read More
Representative image of immuno-oncology research and combination cancer therapy, reflecting Agenus AACR 2026 data on botensilimab, balstilimab, and agenT-797 in PD-1 refractory gastroesophageal cancer.
Pharma & Biotech

Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer

Read how Agenus’ AACR 2026 data could reshape treatment sequencing in refractory gastroesophageal cancer and what risks still matter.

Read More
Representative image of Zai Lab’s zocilurtatug pelitecan story at AACR 2026, highlighting its potential impact on small cell lung cancer brain metastases and neuroendocrine carcinomas.
Pharma & Biotech

AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?

Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.

Read More
Pharma & Biotech

How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy

Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.

Read More
Pharma & Biotech

What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers

Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.

Read More